Prospective Multicenter Nationwide Registry of Children With Eosinophilic Esophagitis

NCT ID: NCT03858426

Last Updated: 2019-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-01

Study Completion Date

2022-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Registry of demographic, clinical, endoscopic and histological data at baseline.
2. Registry of patients treated with PPI:

* Clinical, endoscopic and histological response at 8-12 weeks of induction treatment
* Clinical, endoscopic and histological response at 6 and 12 months weeks of maintenance treatment
3. Registry of patients treated with two foods elimination diet:

* Clinical, endoscopic and histological response at 8-12 weeks of induction treatment
* Identification of food trigger: milk, gluten or milk and gluten
* Clinical, endoscopic and histological response at one year elimination of food trigger
* Registry of adverse events
4. Registry of patients treated with swallowed steroids (budesonide or fluticasone):

* Clinical, endoscopic and histological response at 8-12 weeks of induction treatment
* Clinical, endoscopic and histological response at 6 months of maintenance steroid treatment
* Registry of adverse events

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eosinophilic Esophagitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Eosinophilic Esophagitis; PPIs, children, elimination diet, topical steroids

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children with eosinophilic esophagitis

Inclusion criteria:

* Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus \> 15 eos / CGA)
* And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids

Exclusion criteria:

* Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)
* Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids).

no intervention

Intervention Type OTHER

no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention

no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis (EoE) according to the recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus \> 15 eos / CGA)
* And that they need to start treatment with any of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids .

Exclusion Criteria

* Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)
* Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids).
Minimum Eligible Age

1 Month

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sociedad Espanola de Gastroenterologia, Hepatologia y Nutricion Pediatrica

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Carolina Gutierrez Junquera

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario Puerta de Hierro Majadahonda

Madrid, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Carolina Gutierrez-Junquera, MD, PHD

Role: CONTACT

Phone: +34911916437

Email: [email protected]

Belén Ruiz-Antorán, MD, PHD

Role: CONTACT

Phone: +34911917479

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Carolina Gutierrez Junquera, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RENESE

Identifier Type: -

Identifier Source: org_study_id